Xencor (XNCR) Barclays 28th Annual Global Healthcare Conference summary

Strategic pipeline overview and milestones

• Focus on proprietary pipeline in oncology and autoimmune diseases, leveraging advanced protein engineering technology.

• Lead programs include T-cell engagers for solid tumors and long-acting antibodies for autoimmune diseases.

• Key milestones for 2026–2027: defining dosing and efficacy for lead solid tumor T-cell engagers (XmAb819, XmAb541) and advancing TL1A bispecific and monospecific programs.

XmAb819 clinical development and strategy

• XmAb819 targets ENPP3 in renal cell carcinoma, showing a 25% response rate in heavily pretreated patients.

• Ongoing studies aim to define optimal dosing and priming regimens, with pivotal trial plans for 2027.

• Expansion into earlier lines of therapy is supported by the agent's novel mechanism and tolerability.

• Sub-studies are planned in pre-TKI and TKI-naive patients to assess monotherapy potential.

• Combination strategies with PD-1 and HIF-2 alpha inhibitors are under consideration.

XmAb541 and expansion opportunities

• XmAb541 is being evaluated in ovarian and germ cell tumors, with data expected to clarify its broader potential.

• Expansion cohorts in additional tumor types (papillary renal cell, colorectal, lung) are underway, focusing on biomarker-selected populations.

• Commercialization strategy favors initial monotherapy launches, with potential for rapid scaling.

• Base case is to commercialize assets independently, though partnerships remain an option.